Health knowledge made personal
Join this community!
› Share page:
Search posts:

New Interferon Formulations Promise to Eliminate Injections in Multiple Sclerosis Treatment

Posted Jan 14 2009 8:26pm
Gen News


Nerveda Inc. and Aegis Therapeutics LLC today announced preclinical results from their joint collaboration aimed at developing non-injectable formulations of the beta-interferons.

The beta interferons, beta-1a (tradename Rebif(R)), and beta 1b (tradenames Betaseron(R) and Betaferon(R)) are closely related injectable protein drugs in the interferon family that are used to treat both the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS).

The beta interferons are currently administered by subcutaneous injection and have been proven clinically to slow the advance of multiple sclerosis and reduce the frequency of attacks. Current worldwide combined annual sales of Rebif(R), Betaseron(R) and Betaferon(R) are approximately $4 Billion.

» Read More

Leaving Comments, Suggestions and/or Questions, are Always Appreciated. - Thank you
Post a comment
Write a comment:

Related Searches